Financial

News
Mereo_BioPharma_logo

Mereo fights revolt by largest shareholder Rubric

UK biotech Mereo BioPharma is attempting to face down a revolt by Rubric Capital Management – its largest shareholder holding around 14% of the company – which is agitating for changes to i

News
BMS_Nassau_Park

Opdualag off to a flying start, says BMS CEO

Bristol-Myers Squibb's new immune checkpoint inhibitor combination Opdualag has only been on the US market for a few weeks but is already off to a "great start", according to chief executiv